دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
What is the optimal target for a T2T approach in axial spondyloarthritis?
Joachim Sieper, Denis Poddubnyy
doi : 10.1136/annrheumdis-2021-220603
Annals of the Rheumatic Diseases 2021;80:1367-1369.
Clemens von Pirquet
Clemens Scheinecker, Dietrich Kraft
doi : 10.1136/annrheumdis-2021-220122
Annals of the Rheumatic Diseases 2021;80:1370-1372.
Ultrasound definition of enthesitis in spondyloarthritis and psoriatic arthritis: arrival or starting point?
Emilio Filippucci, Gianluca Smerilli, Andrea Di Matteo, Walter Grassi
doi : 10.1136/annrheumdis-2021-220478
Annals of the Rheumatic Diseases 2021;80:1373-1375.
Enthesitis has a key role in the diagnosis, classification and management of patients with spondyloarthritis and psoriatic arthritis. Clinical assessment of enthesitis is known to be inaccurate mainly due to its poor specificity. In this context, ultrasound has the potential to improve the evaluation of enthesitis and, therefore, the management of patients with spondyloarthritis and psoriatic arthritis. In this viewpoint, we review the Outcome Measures in Rheumatology (OMERACT) definitions for ultrasound enthesitis, highlighting their current limits and potential implications on rheumatology research and clinical practice.
Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
doi : 10.1136/annrheumdis-2021-220512
Annals of the Rheumatic Diseases 2021;80:1376-1384.
There are no head-to-head trials of different dose escalation strategies of methotrexate (MTX) in RA. We compared the efficacy, safety and tolerability of ‘usual’ (5 mg every 4 weeks) versus ‘fast’ (5 mg every 2 weeks) escalation of oral MTX.
Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis
Tate M Johnson, Harlan R Sayles, Joshua F Baker, Michael D George, Punyasha Roul, Cheng Zheng, Brian Sauer, Katherine P Liao, Daniel R Anderson, Ted R Mikuls, Bryant R England
doi : 10.1136/annrheumdis-2021-220125
Annals of the Rheumatic Diseases 2021;80:1385-1392.
Examine the association of methotrexate (MTX) use with cardiovascular disease (CVD) in rheumatoid arthritis (RA) using marginal structural models (MSM) and determine if CVD risk is mediated through modification of disease activity.
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease
Ming-Han Chen, I-Cheng Lee, Ming-Huang Chen, Ming-Chih Hou, Chang-Youh Tsai, Yi-Hsiang Huang
doi : 10.1136/annrheumdis-2021-220774
Annals of the Rheumatic Diseases 2021;80:1393-1399.
Hepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence and risk factors need to be delineated.
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial
Hafsah Nabi, Stylianos Georgiadis, Anne Gitte Loft, Oliver Hendricks, Dorte Vendelbo Jensen, Marlene Andersen, Stavros Chrysidis, Ada Colic, Kamilla Danebod, Mohamad Redha Hussein, Maren Høgberget Kalisz, Salome Kristensen, Niels Lomborg, Natalia Manilo, Heidi Lausten Munk, Jens Kristian Pedersen, Johnny Lillelund Raun, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg
doi : 10.1136/annrheumdis-2021-219951
Annals of the Rheumatic Diseases 2021;80:1400-1409.
In 2018, a nationwide mandatory switch from originator to biosimilar adalimumab was conducted in Denmark. The available biosimilar was GP2017 (Hyrimoz) in Eastern regions and SB5 (Imraldi) in Western regions. We aimed to assess the comparative effectiveness of GP2017 versus SB5 in patients with rheumatoid arthritis (RA)/psoriatic arthritis (PsA)/axial spondyloarthritis (AxSpA).
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Ulf Lindström, Daniela Di Giuseppe, Bénédicte Delcoigne, Bente Glintborg, Burkhard Möller, Adrian Ciurea, Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Kari Eklund, Heikki Relas, Bjorn Gudbjornsson, Thorvardur Jon Love, Gareth T Jones, Catalin Codreanu, Ruxandra Ionescu, Lucie Nekvindova, Jakub Závada, Nuh Atas, Servet Yolbas, Karen Minde Fagerli, Brigitte Michelsen, Žiga Rotar, Matija Tomši?, Florenzo Iannone, Maria Jose Santos, Pedro Avila-Ribeiro, Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Lennart TH Jacobsson, Johan Askling, Michael J Nissen
doi : 10.1136/annrheumdis-2021-220097
Annals of the Rheumatic Diseases 2021;80:1410-1418.
Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy.
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
Josef S Smolen, Stefan Siebert, Tatiana V Korotaeva, Carlo Selmi, Paul Bergmans, Elisa Gremese, Beatriz Joven-Ibáñez, Gkikas Katsifis, Wim Noël, Michael T Nurmohamed, Pascal Richette, Petros P Sfikakis, Kurt de Vlam, Elke Theander, Laure Gossec
doi : 10.1136/annrheumdis-2021-220263
Annals of the Rheumatic Diseases 2021;80:1419-1428.
To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors of low disease activity (LDA)/remission.
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis
Keith Colaco, Ker-Ai Lee, Shadi Akhtari, Raz Winer, Paul Welsh, Naveed Sattar, Iain B McInnes, Vinod Chandran, Paula Harvey, Richard J Cook, Dafna D Gladman, Vincent Piguet, Lihi Eder
doi : 10.1136/annrheumdis-2021-220168
Annals of the Rheumatic Diseases 2021;80:1429-1435.
In patients with psoriatic disease (PsD), we sought serum metabolites associated with cardiovascular (CV) events and investigated whether they could improve CV risk prediction beyond traditional risk factors and the Framingham Risk Score (FRS).
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
Anna Molto, Clementina López-Medina, Filip E Van den Bosch, Annelies Boonen, Casper Webers, Emanuelle Dernis, Floris A van Gaalen, Martin Soubrier, Pascal Claudepierre, Athan Baillet, Mirian Starmans-Kool, Anneke Spoorenberg, Peggy Jacques, Philippe Carron, Rik Joos, Jan Lenaerts, Laure Gossec, Sophie Pouplin, Adeline Ruyssen-Witrand, Laetitia Sparsa, Astrid van Tubergen, Désirée van der Heijde, Maxime Dougados
doi : 10.1136/annrheumdis-2020-219585
Annals of the Rheumatic Diseases 2021;80:1436-1444.
To compare the benefits of a tight-control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA) with those of usual care (UC).
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Ulf Lindström, Karin Bengtsson, Tor Olofsson, Daniela Di Giuseppe, Bente Glintborg, Helena Forsblad-d'Elia, Lennart T H Jacobsson, Johan Askling
doi : 10.1136/annrheumdis-2021-220420
Annals of the Rheumatic Diseases 2021;80:1445-1452.
The effect of interleukin 17-inhibitors on anterior uveitis (AU) in spondyloarthritis (SpA) is poorly understood. This study aimed to compare the risk of AU during treatment with secukinumab versus tumour necrosis factor inhibitors (TNFi).
Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis
Alyxzandria M Gaydosik, Tracy Tabib, Robyn Domsic, Dinesh Khanna, Robert Lafyatis, Patrizia Fuschiotti
doi : 10.1136/annrheumdis-2021-220209
Annals of the Rheumatic Diseases 2021;80:1453-1460.
Although T cells have been implicated in the pathogenesis of systemic sclerosis (SSc), a comprehensive study of T-cell-mediated immune responses in the affected skin of patients with progressive SSc is lacking. Droplet-based single-cell transcriptome analysis of SSc skin biopsies opens avenues for dissecting patient-specific T-cell heterogeneity, providing a basis for identifying novel gene expression related to functional pathways associated with severity of SSc skin disease.
Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies
Weng Ian Che, Helga Westerlind, Ingrid E Lundberg, Karin Hellgren, Ralf Kuja-Halkola, Marie Holmqvist
doi : 10.1136/annrheumdis-2021-219914
Annals of the Rheumatic Diseases 2021;80:1461-1466.
The magnitude of the genetic contribution to idiopathic inflammatory myopathies (IIMs) is unknown. In this project, we aimed to investigate the familial aggregation and heritability of IIM.
Treatment failure in giant cell arteritis
Sebastian H Unizony, Min Bao, Jian Han, Yves Luder, Andrey Pavlov, John H Stone
doi : 10.1136/annrheumdis-2021-220347
Annals of the Rheumatic Diseases 2021;80:1467-1474.
Identify predictors of treatment failure in patients with giant cell arteritis (GCA) receiving tocilizumab in combination with glucocorticoids and in patients with GCA receiving only glucocorticoids.
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis
Cristina Ponte, Sara Monti, Carlo Alberto Scirè, Paolo Delvino, Nikita Khmelinskii, Alessandra Milanesi, Vítor Teixeira, Fabio Brandolino, Fernando Saraiva, Carlomaurizio Montecucco, João Eurico Fonseca, Wolfgang A Schmidt, Raashid Ahmed Luqmani
doi : 10.1136/annrheumdis-2021-220306
Annals of the Rheumatic Diseases 2021;80:1475-1482.
To assess the sensitivity to change of ultrasound halo features and their association with disease activity and glucocorticoid (GC) treatment in patients with newly diagnosed giant cell arteritis (GCA).
Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan
Ruriko Koto, Akihiro Nakajima, Hideki Horiuchi, Hisashi Yamanaka
doi : 10.1136/annrheumdis-2021-220439
Annals of the Rheumatic Diseases 2021;80:1483-1490.
In patients with gout, treating to target serum uric acid levels (sUA) of ?6.0?mg/dL is universally recommended to prevent gout flare. However, there is no consensus on asymptomatic hyperuricaemia. Using Japanese health insurance claims data, we explored potential benefits of sUA control for preventing gout flare in subjects with asymptomatic hyperuricaemia.
Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis
Satoshi Takanashi, Yuko Kaneko, Tsutomu Takeuchi
doi : 10.1136/annrheumdis-2021-220315
Annals of the Rheumatic Diseases 2021;80:1491-1493.
Joint tenderness and ultrasound inflammation in DMARD-naïve patients with early rheumatoid arthritis
Nina Paulshus Sundlisater, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer, Till Uhlig, Désirée van der Heijde, Tore K Kvien, Espen A Haavardsholm, Siri Lillegraven
doi : 10.1136/annrheumdis-2021-220265
Annals of the Rheumatic Diseases 2021;80:1493-1494.
Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis
Moeed Akbar, Lucy MacDonald, Lindsay A N Crowe, Konstantin Carlberg, Mariola Kurowska-Stolarska, Patrik L Ståhl, Sarah J B Snelling, Iain B McInnes, Neal L Millar
doi : 10.1136/annrheumdis-2021-220256
Annals of the Rheumatic Diseases 2021;80:1494-1497.
Effects of face masks on oxygen saturation and functional measures in patients with connective tissue disorder-associated interstitial lung disease
Anuroopa Vijayan, Sakir Ahmed, Sneha Joseph, Aswathy Sukumaran, Subin Ahmed, Padmanabha Shenoy
doi : 10.1136/annrheumdis-2021-220230
Annals of the Rheumatic Diseases 2021;80:1497-1498.
Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group
Francesco Ursini, Piero Ruscitti, Salvatore D'Angelo, Fabio Cacciapaglia, Rossella De Angelis, Corrado Campochiaro, Francesco Caso, Maria De Santis, Ilenia Di Cola, Simone Parisi, Vincenzo Raimondo, Giuseppina Abignano, Luisa Costa, Jacopo Ciaffi, Lorenzo Dagna, Annamaria Iagnocco, Florenzo Iannone, Riccardo Meliconi, Roberto Giacomelli, Clodoveo Ferri
doi : 10.1136/annrheumdis-2021-220606
Annals of the Rheumatic Diseases 2021;80:1498-1501.
Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan
Yohei Kirino, Kaoru Takase-Minegishi, Naomi Tsuchida, Lisa Hirahara, Yosuke Kunishita, Ryusuke Yoshimi, Hideaki Nakajima
doi : 10.1136/annrheumdis-2021-220876
Annals of the Rheumatic Diseases 2021;80:1501-1502.
Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al
Lea C Berkhout, Merel J l'Ami, Gerrit Jan Wolbink, Theo Rispens
doi : 10.1136/annrheumdis-2019-216557
Annals of the Rheumatic Diseases 2021;80:e172.
Response to: ‘Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al’ by Berkhout et al
Yoshiya Tanaka, Koji Oba, Tsutomu Takeuchi
doi : 10.1136/annrheumdis-2019-216593
Annals of the Rheumatic Diseases 2021;80:e173.
Gut-derived CD8+ tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients
Giuliana Guggino, Aroldo Rizzo, Daniele Mauro, Federica Macaluso, Francesco Ciccia
doi : 10.1136/annrheumdis-2019-216456
Annals of the Rheumatic Diseases 2021;80:e174.
Response to: ‘Gut-derived CD8+ tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients’ by Guggino et al
Zoya Qaiyum, Eric Gracey, YuChen Yao, Robert D Inman
doi : 10.1136/annrheumdis-2019-216472
Annals of the Rheumatic Diseases 2021;80:e175.
Gut microbiome in rheumatic diseases
Sergey Moiseev, Vilen Rameev, Ekaterina Karovaikina, Lidia Lysenko (Kozlovskaya)
doi : 10.1136/annrheumdis-2019-216560
Annals of the Rheumatic Diseases 2021;80:e176.
The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus
Sheng-Xiao Zhang, Jia Wang, Jun-Wei Chen, Ming-Xing Zhang, Yi-Fan Zhang, Fang-Yuan Hu, Zhi-Qin Lv, Chong Gao, Ya-Feng Li, Xiao-Feng Li
doi : 10.1136/annrheumdis-2019-216504
Annals of the Rheumatic Diseases 2021;80:e177.
Response to: ‘The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus’ by Zhang et al and the phylogeny of a candidate pathobiont in lupus nephritis
Gregg J Silverman, Doua F Azzouz
doi : 10.1136/annrheumdis-2019-216523
Annals of the Rheumatic Diseases 2021;80:e178.
Bone health in patients with systemic lupus erythematosus
Shih-Wei Lai, Yu-Hung Kuo, Kuan-Fu Liao
doi : 10.1136/annrheumdis-2019-216417
Annals of the Rheumatic Diseases 2021;80:e179.
Association between osteoporosis and statins therapy
Shih-Wei Lai
doi : 10.1136/annrheumdis-2019-216464
Annals of the Rheumatic Diseases 2021;80:e180.
Response to: ‘Association between osteoporosis and statins therapy’ by Lai
Michael Leutner, Caspar Matzhold, Luise Bellach, Carola Deischinger, Jürgen Harreiter, Stefan Thurner, Peter Klimek, Alexandra Kautzky-Willer
doi : 10.1136/annrheumdis-2019-216494
Annals of the Rheumatic Diseases 2021;80:e181.
Anti-Ku antibodies: important points to consider
Michael Mahler, Minoru Satoh, Marvin J Fritzler
doi : 10.1136/annrheumdis-2019-216535
Annals of the Rheumatic Diseases 2021;80:e182.
Response to: ‘Anti-Ku antibodies: important points to consider’ by Mahler et al
Mariko Ogawa-Momohara, Yoshinao Muro, Masashi Akiyama
doi : 10.1136/annrheumdis-2019-216595
Annals of the Rheumatic Diseases 2021;80:e183.
Temporal ultrasound for monitoring tocilizumab treatment in giant cell arteritis: seeing beyond serum markers?
Gerasimos Evangelatos, George E Fragoulis, Alexios Iliopoulos
doi : 10.1136/annrheumdis-2019-216527
Annals of the Rheumatic Diseases 2021;80:e184.
Involvement of industry in review articles published in Annals of the Rheumatic Diseases
Martin Rudwaleit
doi : 10.1136/annrheumdis-2019-216544
Annals of the Rheumatic Diseases 2021;80:e185.
Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study
doi : 10.1136/annrheumdis-2020-216980corr2
Annals of the Rheumatic Diseases 2021;80:e186.
Correction: Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
doi : 10.1136/annrheumdis-2020-219446corr1
Annals of the Rheumatic Diseases 2021;80:e187.
